Sign Up
Stories
AB-2100 Phase 1/2 Trial Initiated
Share
AI-Powered Antigen Research Partnership
Adagene Advances Clinical Collaboration
Advanced Ovarian Cancer Treatment Breakt...
Affini-T Therapeutics at J.P. Morgan Hea...
Anocca Appoints Martin Welschof to Board...
Atara Biotherapeutics at Health Conferen...
Overview
API
Arsenal Biosciences doses first patient with AB-2100 in a Phase 1/2 trial for ccRCC treatment.
Ask a question
How does the CITE-engineered approach of AB-2100 differ from traditional cancer treatments?
How might the success of this trial impact the landscape of renal cell carcinoma treatments?
What are the implications of targeting ccRCC patients resistant to checkpoint and VEGF inhibitors?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Apr 2024
Coverage